APLS — Apellis Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $6.24bn
- $6.30bn
- $396.59m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 32.1 | ||
| Price to Tang. Book | 32.1 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 15.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -95.56% | ||
| Return on Equity | -290.14% | ||
| Operating Margin | -130.39% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 250.65 | 66.56 | 75.42 | 396.59 | 795.38 | 1,182.05 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
Directors
- Gerald Chan NEC (70)
- Cedric Francois PRE (48)
- Pascal Deschatelets CFD (51)
- Timothy Sullivan CFO (50)
- Nur Nicholson COO (52)
- James Chopas CAO (55)
- Nicole Perry VPR (56)
- David Watson GCN (48)
- Federico Grossi OTH (46)
- Lukas Scheibler OTH (50)
- Adam Townsend OTH (44)
- A. Sinclair Dunlop IND (49)
- Paul Fonteyne IND (59)
- Alec Machiels IND (48)
- Stephanie O'Brien IND (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 25th, 2009
- Public Since
- November 9th, 2017
- No. of Shareholders
- 5
- No. of Employees
- 702
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 120,581,749
- Address
- 100 Fifth Avenue, WALTHAM, 02451
- Web
- https://apellis.com/
- Phone
- +1 6179775700
- Contact
- Meredith Kaya
- Auditors
- Deloitte & Touche LLP
Upcoming Events for APLS
Apellis Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Apellis Pharmaceuticals Inc Earnings Release
Similar to APLS
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
What is the Apellis Pharmaceuticals share price?
As of Today at 19:02 UTC, shares in Apellis Pharmaceuticals are trading at $51.79. This share price information is delayed by 15 minutes.
How has the Apellis Pharmaceuticals share price performed this year?
Shares in Apellis Pharmaceuticals last closed at $51.79 and the price had moved by -34.58% over the past 365 days. In terms of relative price strength the Apellis Pharmaceuticals share price has underperformed the S&P500 Index by -47.16% over the past year.
What are the analyst and broker recommendations for Apellis Pharmaceuticals?
The overall consensus recommendation for Apellis Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Apellis Pharmaceuticals dividend yield?
Apellis Pharmaceuticals does not currently pay a dividend.
Does Apellis Pharmaceuticals pay a dividend?
Apellis Pharmaceuticals does not currently pay a dividend.
When does Apellis Pharmaceuticals next pay dividends?
Apellis Pharmaceuticals does not currently pay a dividend.
How do I buy Apellis Pharmaceuticals shares?
To buy shares in Apellis Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Apellis Pharmaceuticals?
As of the previous close price of $51.79, shares in Apellis Pharmaceuticals had a market capitalisation of $6.24bn.
Where are Apellis Pharmaceuticals shares listed?
Here are the trading details for Apellis Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: APLS
What kind of share is Apellis Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Apellis Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Apellis Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Apellis Pharmaceuticals is $82.80. That is 59.88% above the last closing price of $51.79.
Analysts covering Apellis Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.23 for the next financial year.
What is the trend in the Apellis Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Apellis Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -8.73%.
As of the last closing price of $51.79, shares in Apellis Pharmaceuticals were trading -3.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Apellis Pharmaceuticals PE Ratio?
The Apellis Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $51.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Apellis Pharmaceuticals?
Apellis Pharmaceuticals' management team is headed by:
- Gerald Chan - NEC
- Cedric Francois - PRE
- Pascal Deschatelets - CFD
- Timothy Sullivan - CFO
- Nur Nicholson - COO
- James Chopas - CAO
- Nicole Perry - VPR
- David Watson - GCN
- Federico Grossi - OTH
- Lukas Scheibler - OTH
- Adam Townsend - OTH
- A. Sinclair Dunlop - IND
- Paul Fonteyne - IND
- Alec Machiels - IND
- Stephanie O'Brien - IND